Emgality Receives First FDA Approval for Treating Cluster Headache

TUESDAY, June 4, 2019 — The U.S. Food and Drug Administration granted Emgality (galcanezumab-gnlm) solution the first approval for treating episodic cluster headache, the agency announced yesterday.
Previously approved for preventive treatment of…
Source: Topamax